Weekly Report: what happened at FGEN last week (0715-0719)?
Weekly Report · 3d ago
Weekly Report: what happened at FGEN last week (0708-0712)?
Weekly Report · 07/15 09:07
Weekly Report: what happened at FGEN last week (0701-0705)?
Weekly Report · 07/08 09:08
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Qualigen Therapeutics (NASDAQ:QLGN) shares moved upwards by 42.5% to $0.25 during Thursday's regular session. Akso Health Group stock rose 11.68% and Sharps Technology stock rose 33.56% during the session.
Benzinga · 07/04 16:31
Little Excitement Around FibroGen, Inc.'s (NASDAQ:FGEN) Revenues As Shares Take 44% Pounding
FibroGen, Inc. Shares are down a considerable 44% in the last month. FibroGen's price-to-sales ratio of 0.4x is lower than the wider Biotechs industry. The company's revenue growth has been slower than most other companies. Its outlook for shrinking revenue is contributing to its low P/S ratio.
Simply Wall St · 07/04 10:00
Weekly Report: what happened at FGEN last week (0624-0628)?
Weekly Report · 07/01 09:08
FibroGen files for $300M mixed shelf offering
FibroGen files for $300M mixed shelf offering Jun. 28, 2024. FibroGen, Inc. (NASDAQ:FGEN) stock down 1.5%. Fibrogen says it has filed a prospectus for a mixed shelf offer of up to $300 million.
Seeking Alpha · 06/28 21:32
Reuters · 06/28 21:09
Goldman Sachs Sticks to Its Sell Rating for FibroGen (FGEN)
TipRanks · 06/26 19:15
Weekly Report: what happened at FGEN last week (0617-0621)?
Weekly Report · 06/24 09:08
FibroGen, Inc.'s (NASDAQ:FGEN) recent 11% pullback adds to one-year year losses, institutional owners may take drastic measures
Institutional investors own 59% of FibroGen, Inc. (NASDAQ:FGEN) with a majority of the company. 10 investors have a majority stake in the company with 52% of the shares. The company's share price fell by 11% last week. Fibrogen is owned by a group of institutions with a significant influence over the company's stock price. More than half the shares are owned by the top 10 shareholders of the firm. It's worth looking at Fibro Gen's insider ownership to see if the company has been bought recently.
Simply Wall St · 06/20 11:01
Weekly Report: what happened at FGEN last week (0610-0614)?
Weekly Report · 06/17 09:08
Weekly Report: what happened at FGEN last week (0603-0607)?
Weekly Report · 06/10 09:08
FibroGen: Two New In-Licensed Oncology Drugs To Carry It Forward
FibroGen, Inc. Has shifted its focus into developing drugs to treat patients with cancer. Two drugs being developed as part of FibroGen's pipeline are FG-3165 andFG-3175. The drugs are in-licensed for the treatment of patients with solid tumors. The company has signed a collaboration agreement with Regeneron Pharmaceuticals to advance these drugs.
Seeking Alpha · 06/06 16:38
What's Going On With FibroGen Stock Tuesday?
FibroGen announced the FDA cleared its IND of FG-3165, allowing the company to initiate a Phase 1 clinical trial. FibroGen also announced a new clinical trial supply agreement with Regeneron Pharmaceuticals. The company's shares initially traded higher Tuesday morning.
Benzinga · 06/04 18:27
Stock Index Futures Slip on Growth Fears, U.S. JOLTs Report in Focus
NASDAQ · 06/04 11:25
Why HealthEquity Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Shares of Healthequity Inc rose sharply in today's pre-market trading. The company reported better-than-expected first-quarter financial results. MicroAlgo Inc rose 209.5% to $4.83. Core Scientific shares gained 51.8% in pre- market trading after the company announced plans to establish a quantum research center.
Benzinga · 06/04 09:50
Stock Index Futures Slip Ahead of U.S. JOLTs Report
June S&P 500 E-Mini futures are down -0.55% this morning ahead of the latest reading on U.S. Job openings. In yesterday's trading session, Wall Street's major indexes ended mixed. Paramount Global was the top percentage gainer on the S&p 500 and Boeing rose nearly +4%. Today, investors will focus on the U.s. JOLTs Job Openings data for April.
Barchart · 06/04 04:49
FibroGen stock rallies 30% after hours on FG-3165, FG-3175 updates
FibroGen stock rallies 30% after hours on FG-3165,FG-3175 updates. The company announced clinical updates on its drug candidates. The biotech company said the FDA has cleared its application to begin Phase 1 testing of the drug. FibroGen also said it has entered into a supply agreement with Regeneron.
Seeking Alpha · 06/03 21:38
FibroGen Stock Is Surging After The Bell: What's Going On?
FibroGen Inc (NASDAQ:FGEN) shares are moving higher in Monday's after-hours session. The company announced the FDA cleared its Investigational New Drug for FG-3165. FibroGen also announced a new clinical trial supply agreement with Regeneron.
Benzinga · 06/03 20:48
Webull provides a variety of real-time FGEN stock news. You can receive the latest news about Fibrogen Inc through multiple platforms. This information may help you make smarter investment decisions.
About FGEN
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer and Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. It also develops FG-3165: Anti-Gal9 Antibody and FG-3175: Anti-CCR8 Antibody.